Henning Willers, Director of the MGH Thoracic Radiation Oncology and Radiation Biology Program, shared a post on X about a paper by Hongfu Sun et al. published in the Journal of Clinical Oncology:

“Thoracic Radiotherapy Improves the Survival in Patients With EGFR-Mutated Oligo-Organ Metastatic Non–Small Cell Lung Cancer Treated With Epidermal Growth Factor Receptor–Tyrosine Kinase Inhibitors: A Multicenter, Randomized, Controlled, Phase III Trial”

Authors: Hongfu Sun, Minghao Li, Wei Huang, Zicheng Zhang, Baosheng Li et al.

Henning Willers: A randomized trial from China on primary lung cancer

“Randomized trial out of China: Better PFS/OS for EGFR TKI + 60 Gy to primary lung cancer and LNs but also more toxicity

However:

imbalance in prognostic factors favors radiotherapy group
early separation of PFS curves suggests imbalance of prognostic factors

Am I wrong?”

Drew Moghanaki, Professor and Chief of Thoracic Oncology at the Department of Radiation Oncology at UCLA, shared this post, adding:

“From my perspective, these data show that patients managed with TKI’s that aren’t working well can live longer with some vs no XRT. Whether the TKI is an older or newer generation.”

More posts featuring Henning Willers and Drew Moghanaki.